RxDoctor Payments Data

Ralph Essien, MD

General Practice · New Rochelle, NYNPI 1679668370

Payments from drug & device makers

$4,032in general payments, 2019–2025

Across 202 payments — averaging $19.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$796
  • Boehringer Ingelheim$671
  • Lilly USA, LLC$377
  • Exact Sciences$279
  • Novo Nordisk$263
  • Novartis$253
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$3,97299%
  • Education$601%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,032 in reported general payments places this provider in the 95th percentile of 5,764 general practice providers in New York.

See all general practice providers in New York

Medicare billing

Part B allowed, 2024
$90,804
Medicare patients
83
Services billed
1,871

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide78$103,876
TrulicityDulaglutide51$67,005
RybelsusSemaglutide36$64,680
JanuviaSitagliptin Phosphate77$59,348
JardianceEmpagliflozin32$42,649
MounjaroTirzepatide23$32,875
TradjentaLinagliptin41$31,467
EntrestoSacubitril/Valsartan22$26,179
JanumetSitagliptin Phos/Metformin Hcl17$14,798
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog30$13,094
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$12,955
Breo ElliptaFluticasone/Vilanterol28$12,866
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$8,321
KerendiaFinerenone12$7,401
JentaduetoLinagliptin/Metformin Hcl16$7,322

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$263$168,556114 claims
Lilly USA, LLCTrulicity, Mounjaro$377$99,88074 claims
Boehringer IngelheimJardiance, Tradjenta, Jentadueto$671$81,43889 claims
MerckJanuvia, Janumet$39$74,14794 claims
NovartisEntresto$253$26,17922 claims
AstraZenecaBreztri Aerosphere$796$12,95521 claims
GSKBreo Ellipta$134$12,86628 claims
BayerKerendia$132$7,40112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,764 general practice providers in New York.

Other general practice in New Rochelle

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →